Back

TET2 loss promotes premalignant survival and clonal selection in MYC-driven B cell lymphoma

Spoeck, S.; Kinz, N.; Rigato, I.; Hoppe, K.; Heppke, J.; Petermann, P. Y.; Weiss, J. G.; Erlacher, M.; Schubert, M.; Riley, J. S.; Villunger, A.; Finotello, F.; Labi, V.

2026-03-21 cancer biology
10.64898/2026.03.20.712678 bioRxiv
Show abstract

The DNA demethylase ten-eleven translocation enzyme 2 (TET2) is frequently inactivated in hematologic malignancies, yet how its loss shapes oncogene-driven transformation remains unclear. Using a mouse model in which MYC is overexpressed in the B cell lineage, driving aggressive B cell lymphoma, we show that Tet2 loss increases lymphoma penetrance and biases disease toward an IgM immunophenotype. Established lymphomas are broadly similar across genotypes, suggesting that Tet2 loss exerts much of its effects before lymphoma onset. Accordingly, Tet2 loss expands a premalignant IgM B cell subset with reduced apoptotic sensitivity and an increased frequency of BCL2BIMhi cells. Consistently, Tet2 deficient IgM B cells persist better in in vitro cultures, show increased clonogenic survival, and exhibit clonal skewing. These findings support a model in which Tet2 loss heightens MYC-driven lymphoma penetrance by promoting the survival and selection of premalignant B cells under apoptotic stress.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.